FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

BACKGROUND: The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer do not benefit the same from treatment than RAS-wildtype metastatic colorectal...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Adenis, Antoine, Mazard, Thibault, Fraisse, Julien, Chalbos, Patrick, Pastor, Brice, Evesque, Ludovic, Ghiringhelli, Francois, Mollevi, Caroline, Delaine, Stéphanie, Ychou, Marc
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Study Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130420/
https://ncbi.nlm.nih.gov/pubmed/34001059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08312-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items